Landewé, Robert

Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0

Boers, M., Kirwan, J. R., Wells, G., Beaton, D., Gossec, L., d'Agostino, M.-A., Conaghan, P. G., Bingham, C. O., Brooks, P., Landewé, R., et al. (2014) · Journal of Clinical Epidemiology

Delphi Technique in ResearchHealth Systems, Economic Evaluations, Quality of Life

Cited by 781

The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.

Geusens, P. P., Landewé, R. B. M., Garnero, P., Chen, D., Dunstan, C. R., Lems, W. F., Stinissen, P., van der Heijde, D. M. F. M., van der Linden, S., & Boers, M. (2006) · Arthritis & Rheumatism

Rheumatoid Arthritis Research and TherapiesBone Metabolism and Diseases

Cited by 182

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

Rondaan, C., Furer, V., Heijstek, M. W., Agmon-Levin, N., Bijl, M., Breedveld, F. C., D’Amelio, R., Dougados, M., Kapetanovic, M. C., van Laar, J. M., et al. (2019) · RMD Open

Rheumatoid Arthritis Research and TherapiesVaccine Coverage and Hesitancy

Cited by 154

Two different invitation approaches for consecutive rounds of a Delphi survey led to comparable final outcome

Boel, A., Navarro-Compán, V., Landewé, R., & van der Heijde, D. (2021) · Journal of Clinical Epidemiology

Delphi Technique in ResearchSurvey Methodology and Nonresponse

Cited by 118

How the type of risk reduction influences required sample sizes in randomised clinical trials

Bruynesteyn, K., Wanders, A., Landewé, R., & van der Heijde, D. (2004) · Annals of the Rheumatic Diseases

Statistical Methods in Clinical TrialsStatistical Methods in Epidemiology

Cited by 5